The health and economic burden of smoking in 12 Latin American countries and the potential effect of increasing tobacco taxes: an economic modelling study by Pichón-riviere, Andres et al.
Articles
www.thelancet.com/lancetgh 1
The health and economic burden of smoking in 12 Latin 
American countries and the potential effect of increasing 
tobacco taxes: an economic modelling study 
Andrés Pichon-Riviere, Andrea Alcaraz, Alfredo Palacios, Belén Rodríguez, Luz Myriam Reynales-Shigematsu, Márcia Pinto, 
Marianela Castillo-Riquelme, Esperanza Peña Torres, Diana Isabel Osorio, Leandro Huayanay, Cesar Loza Munarriz, Belén Sáenz de Miera-Juárez, 
Verónica Gallegos-Rivero, Catherine De La Puente, María del Pilar Navia-Bueno, Joaquín Caporale, Javier Roberti, Sacha Alexis Virgilio, 
Federico Augustovski, Ariel Bardach
Summary
Background Worldwide, smoking tobacco causes 7 million deaths annually, and this toll is expected to increase, 
especially in low-income and middle-income countries. In Latin America, smoking is a leading risk factor for death 
and disability, contributes to poverty, and imposes an economic burden on health systems. Despite being one of the 
most effective measures to reduce smoking, tobacco taxation is underused and cigarettes are more affordable in 
Latin America than in other regions. Our aim was to estimate the tobacco-attributable burden on mortality, disease 
incidence, quality of life lost, and medical costs in 12 Latin American countries, and the expected health and economic 
effects of increasing tobacco taxes.
Methods In this modelling study, we developed a Markov probabilistic microsimulation economic model of the 
natural history, medical costs, and quality-of-life losses associated with the most common tobacco-related diseases in 
12 countries in Latin America. Data inputs were obtained through a literature review, vital statistics, and hospital 
databases from each country: Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Ecuador, Honduras, Mexico, 
Paraguay, Peru, and Uruguay. The main outcomes of the model are life-years, quality-adjusted life-years, disease 
events, hospitalisations, disease incidence, disease cost, and healthy years of life lost. We estimated direct medical 
costs for each tobacco-related disease included in the model using a common costing methodology for each country. 
The disease burden was estimated as the difference in disease events, deaths, and associated costs between the results 
predicted by the model for current smoking prevalence and a hypothetical cohort of people in each country who had 
never smoked. The model estimates the health and financial effects of a price increase of cigarettes through taxes, in 
terms of disease and health-care costs averted, and increased tax revenues.
Findings In the 12 Latin American countries analysed, we estimated that smoking is responsible for approximately 
345 000 (12%) of the total 2 860 921 adult deaths, 2·21 million disease events, 8·77 million healthy years of life lost, 
and $26·9 billion in direct medical costs annually. Health-care costs attributable to smoking were estimated to 
represent 6·9% of the health budgets of these countries, equivalent to 0·6% of their gross domestic product. Tax 
revenues from cigarette sales cover 36·0% of the estimated health expenditures caused by smoking. We estimated 
that a 50% increase in cigarette price through taxation would avert more than 300 000 deaths, 1·3 million disease 
events, gain 9 million healthy life-years, and save $26·7 billion in health-care costs in the next 10 years, with a total 
economic benefit of $43·7 billion.
Interpretation Smoking represents a substantial health and economic burden in these 12 countries of Latin America. 
Tobacco tax increases could successfully avert deaths and disability, reduce health-care spending, and increase tax 
revenues, resulting in large net economic benefits.
Funding International Development Research Centre (IDRC), Canada.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license. 
Introduction
Worldwide, smoking tobacco is expected to cause 
7·5 million deaths in 2020 and is the second biggest risk 
factor for death and disability.1,2 Tobacco is responsible 
for 65% of deaths due to lung cancer worldwide, 44% of 
deaths due to chronic obstructive pulmonary disease, 
and 22% of deaths due to ischaemic heart disease.1,3 
Moreover, smoking-related diseases cause a substantial 
economic burden on individuals and health systems, 
which can be up to US$500 billion globally per year, 
including costs of productivity loss, illnesses, and 
premature deaths, representing up to 1·5% of the gross 
domestic product of individual countries and up to 15% 
of all national health expenditures.4
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The WHO Framework Convention on Tobacco Control 
(FCTC) is included in the Sustainable Development 
Goals, signed by more than 100 countries in 
September 2015, at the UN General Assembly. Among 
the measures proposed in the FCTC, an increase in the 
inflation-adjusted price of tobacco is a realistic and 
effective strategy to reduce smoking because, despite the 
highly addictive nature of cigarettes, the demand for 
tobacco is strongly influenced by its price.5 However, only 
a few countries have substantially increased specific 
excise taxes on tobacco in an attempt to reduce smoking.5 
Indeed, raising taxes on tobacco is the least often 
implemented measure of those established by the FCTC. 
It is estimated that increasing cigarette taxes by 10% 
would increase tax revenues by an additional 7%; 
however, in most low-income and middle-income 
countries, cigarette taxes are under used.3 Many countries 
have extremely low tobacco tax rates, and some countries 
do not levy any tobacco taxes.6
In Latin America, smoking is among the five leading 
risk factors for death and disability, and contributes to 
poverty via decreased productivity and an impact on out-
of-pocket expenses.2,7 Smoking accounts for $34 billion in 
direct medical costs every year, which represents a 
substantial proportion of Latin American health budgets.8 
Most Latin American countries have signed the FCTC, 
but many still do not have a strong tobacco-control policy. 
Misinformation, prejudice, an absence of country-level 
comprehensive data, and pressure from interest groups 
have delayed the implementation and the enforcement of 
key measures in Latin America.9 Many of these measures, 
such as tax increases, are also politically challenging. To 
foster the implementation of effective tobacco-control 
policies in the region, it is necessary to obtain relevant, 
country-level information on the health and economic 
consequences of smoking tobacco and how these relate 
to individuals, families, communities, and countries. 
Moreover, this information is needed to raise awareness 
and advocate for the adoption of measures and 
mobilisation of resources to control tobacco. The absence 
of reliable information in several countries in the region 
on the true burden of smoking, and on the potential effect 
of the interventions, delays the application of stronger 
measures. The aims of this study are to estimate the 
tobacco-related burden on disease, mortality, and direct 
medical costs in 12 countries in Latin America, and to 
estimate the health and financial effect of different levels 
of tobacco taxation.
Methods
Study design and model development
This economic modelling study estimated the tobacco-
related burden on disease and the potential effect and 
cost-effectiveness of tobacco control interventions in 
12 Latin American countries: Argentina, Bolivia, Brazil, 
Chile, Colombia, Costa Rica, Ecuador, Honduras, Mexico, 
Paraguay, Peru, and Uruguay. The study was part of a 
collaborative project that included researchers, decision 
makers, and academic institutions from these 
12 countries.
To inform the model development, we did a compre-
hensive analysis of the availability and quality of 
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Evidence before this study
We searched PubMed on Sept 15, 2019, using the search terms 
(tobacco use disorder[MeSH] OR tobacco use[tiab] OR 
smoking[MeSH] OR smoking[tiab] OR cigar*[tiab]) AND (cost 
of illness[MeSH] OR models, economic[MeSH] OR “costs and 
cost analysis”[MeSH] OR taxes[MeSH] OR taxation*[tiab]) AND 
(Argentina[MeSH] OR Bolivia[MeSH] OR Brazil[MeSH] OR 
Chile[MeSH] OR Colombia[MeSH] OR Costa Rica[MeSH] OR 
Ecuador[MeSH] OR Honduras[MeSH] OR Mexico[MeSH] OR 
Paraguay[MeSH] OR Peru[MeSH] OR Uruguay[MeSH] OR Latin 
America[MeSH]). We searched for primary research, modelling 
studies, and reviews published between Jan 1, 2010, and 
Aug 31, 2019, with no language restrictions. We found 
20 studies on models and disease burden, 16 reviews, 
15 articles about taxation, and three primary research reports. 
Smoking is a leading risk factor for premature morbidity and 
mortality. If trends are not reversed, the tobacco-attributable 
burden on health and economies will continue to increase in 
low-income and middle-income countries. High excise taxes on 
tobacco could be essential to reduce tobacco use, but they are 
underused in Latin America. There are few published studies 
that have quantified both the burden of tobacco and the 
impact of higher tobacco taxes on health and financial 
outcomes in Latin America.
Added value of this study
Our study shows that smoking tobacco causes a substantial 
proportion of the burden of disease and health-care costs in 
12 Latin American countries each year. Current tobacco taxes 
cover just 36·0% of the direct medical costs caused by smoking 
in these countries. We estimate that a 50% increase in tobacco 
prices would save around 300 000 deaths and 9 million healthy 
life-years in the next 10 years; and would produce economic 
benefits of more than US$40 billion because of averted 
treatment costs and increased tax revenues.
Implications of all the available evidence
Higher tobacco taxes could be one of the most powerful tools 
to decrease the use of tobacco. In Latin America, tobacco 
taxation is underused, and cigarettes are more affordable than 
in other regions. Evidence supports that higher tobacco taxes 
can reduce tobacco use, avert tobacco-related mortality and 
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epidemiological and health-care cost data in the region, 
and of policy makers’ information needs for the imple-
mentation of tobacco-control interventions. The model is 
a state transition or Markov probabilistic microsimulation 
of individuals (first-order Monte Carlo technique) 
including natural history, direct medical costs, and quality-
of-life losses associated with the most common tobacco-
related diseases (coronary and non-coronary heart disease, 
cerebrovascular disease, chronic obstructive pulmonary 
disease, pneumonia, influenza, lung cancer, and nine 
other neoplasms).
During the past 9 years, the model was validated and 
used in various Latin American countries to estimate the 
burden of disease attributable to smoking and the 
potential effect of different interventions. More detail can 
be found in previous publications8,10–14 and in the reports 
and technical documents for the 12 countries included in 
this analysis.
Baseline incidence risks in people who had never 
smoked tobacco were estimated for each health condition 
and each country from mortality statistics. For acute 
events, age and sex specific incidence (absolute risk) was 
calculated on the basis of specific mortality and the 
lethality of the event as
where Rdeath is the specific mortality per age and sex and 
L is lethality. Once the absolute risk was obtained, the 
baseline risk for people who had never smoked tobacco 
was calculated from the specific prevalence of tobacco 
use per age and sex, as well as the relative risk (RR) for 
each condition for people who currently smoke or 
formerly smoked:
In this calculation, Rnonsmk is the annual incidence of the 
acute disease event for people who have never smoked, 
Rpop.event is the specific population risk per age and sex (from 
the previous formula), RRsmk and RRfrsmk are the relative 
risks of the event in people who smoke and people who 
used to smoke versus people who have never smoked, and 
fsmk, ffrsmk, and fnonsmk are the specific proportions of people 
who smoke, people who used to smoke, and people who 
have never smoked per age and sex (the RRs by condition 
are in the appendix, p 3).
For lung cancer, the annual incidence for each age and 
sex strata was calculated from annual mortality rates 
from national statistics and the annual estimated survival 
after diagnosis:
where Rdxi is the estimated incidence at age i, RM(i + n) is the 
general population risk of death at age i + n, Pn is the 
conditional probability of dying in year n after being 
diagnosed, and S10 is the proportion of individuals 
surviving after 10 years. For other cancers, specific 
incidence rates for each age and sex strata were estimated 
from Global Cancer Observatory data for each country.15
Individuals were followed up in hypothetical cohorts, 
from age 35 years to death, and the model estimated in 
annual cycles the individual risks of disease incidence, 
disease progression, and death, on the basis of the 
individual’s demographic attributes, smoking status, 
previous clinical conditions, and underlying risk equa-
tions. Using the simulation of each individual’s lifetime, 
health outcomes were calculated to obtain aggregated 
results. The main outcomes of the model are life-years, 
quality-adjusted life years, disease events, hospitalisations, 
disease incidence, disease cost, and healthy years of life 
lost (which aggregate health losses both due to years lost 
by premature mortality as well as quality of life losses).
Information sources
Data to populate the model were obtained through a 
comprehensive review of the literature. The following 
electronic databases were used: MEDLINE, Embase, 
Cochrane Central Register of Controlled Trials, SocINDEX, 
EconLit, Latin American and Caribbean Health Sciences 
Literature, National Bureau of Economic Research, Centre 
for Reviews and Dissemination and Cost Effectiveness 
Analysis Registry, the International Tobacco Health 
Conference Paper Index, and Cochrane Tobacco Addiction 
Review Group register. Grey literature was reviewed from 
ministries of health, ministries of finance, Pan American 
Health Organization, and data bases containing regional 
congress proceedings. Updated information on tobacco 
use prevalence was obtained from local tobacco Global 
Adult Tobacco Surveys, where available, or national risk 
factor surveys. Researchers from the participating 
countries provided additional information on civil regis-
trations, vital statistics, and hospital discharge databases 
to estimate specific case fatality rates.
Cost data
The direct medical costs (including of diagnosis, 
treatment, and follow-up), from the perspective of the 
public health-care systems, were estimated for each of 
the tobacco-related diseases included in the model. A 
common costing methodology was developed for the 
12 countries, including a microcosting or macro costing 
approach, depending on the availability and quality of 
information in each country. A Microsoft Excel spread-
sheet was designed for each event, identifying health 
resources and measuring quantities, utilisation rates, and 
unit costs for each resource used in each event. These ad-
hoc microcosting exercises were constructed on the basis 
of communications with experts, clinical guidelines, 
and a review of health-care facility records. Costs of 
For reports from Instituto de 
Efectividad Clinica y Sanitaria 
see www.iecs.org.ar/tabaco
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malignancies other than lung cancer were estimated on 
the basis of lung cancer costs and an expert consensus 
obtained through a modified Delphi panel method. When 
sufficient local information was unavail able, indirect 
estimates were used to approximate costs of events (eg, 
for each country with information on the cost of a 
particular health event, the ratio between the cost of the 
health event and the country’s gross domestic product per 
capita was calculated; then, for each country with missing 
cost data, the average of these ratios was applied to their 
gross domestic product per capita to derive the cost of 
the health event). All direct medical costs were estimated 
in local currency units; then consumer price indices 
(published by the statistics institutes of each country) 
were used for adjustments. Finally, costs were converted 
to US dollars using the exchange rates of December, 2015, 
published by the central banks of each country.
Model calibration and validation process
We applied the International Society for Pharmaco-
economics and Outcomes Research criteria for model 
development and reporting.16 To calibrate the model, 
disease specific mortality by sex and age were compared 
with local statistics; predicted mortality within 10% of 
the references were considered acceptable. In case of 
greater deviation, risk equations were modified. External 
validation was accomplished by checking the model 
results against those results of other epidemiological 
and clinical studies not used for equation estimation and 
development.
Estimation of the smoking-related disease burden 
The disease burden was estimated as the difference in 
disease events, deaths, and associated costs between the 
results predicted by the model for each country for 
current smoking prevalence and a hypothetical cohort 
of people who had never smoked for each country. 
Given that the model does not directly calculate the 
consequences of passive smoking and perinatal effects, 
on the basis of the results of previous studies, it was 
estimated that these two causes impose an additional 
burden of 13·6% for men and 12% for women.17 Disease 
burden results are reported for one calendar year (2015).
Estimation of the effect of taxation
The effect of price increases on the prevalence of 
smoking was calculated as
where PrevB is the baseline prevalence of smoking 
before price increase; ∆P is the price variation as a 
proportion of the baseline price; Ip is proportion of the 
variation on cigarette consumption expected to affect 
smoking prevalence; and Ed is the price elasticity of 
demand for cigarettes. Price elasticity gives the 
percentage change in quantity demanded for each 
percentage increase in price (eg, a value of –0·6 means 
that for every 1% increase in price the demand will 
decrease by 0·6%).
Three scenarios were considered to estimate the 
reduction of the health burden associated with the 
reduction in cigarette consumption. (1) A short-term and 
conservative scenario: different studies have estimated 
that in the short-term and medium-term, approximately 
half of the reduction in consumption is a consequence of 
reduced prevalence of smoking and the other half is 
explained by reduced consumption by people who 
continue to smoke.18,19 In this scenario, we assume that 
50% of the reduced consumption is a consequence of the 
reduction in prevalence (Ip=0·5), leading to an increase in 
the number of people who formerly smoked. (2) A 
medium-term scenario: similar to the short-term scenario 
but including potential health benefits associated with the 
reduction in the number of cigarettes smoked by people 
who continue to smoke. Considering that low-intensity 
smokers have an average of 75% less excess disease risk 
than high-intensity smokers when compared with people 
who have never smoked (82% less for lung cancer, 57% 
less for ischaemic heart disease, and 80% less for COPD),20 
we assumed that a reduction in the number of cigarettes 
smoked would result in a proportional reduction in the 
75% of the excess risk difference between a person who 
smokes and a person who formerly smoked. (3) A long-
term scenario: this is the maximum effect scenario 
analysed. It is similar to the medium-term scenario, but 
here Ip=0·75 and the entire reduction in prevalence results 
in an increased population of people who have never 
smoked, instead of one of people who formerly smoked 
(further details in appendix p 4).
To do a unified analysis of the three scenarios, we 
developed a base-case with the results accumulated over 
10 years. We assumed a linear progression from scenario 
one to scenario two over 5 years and a progression to 
scenario three in years 6–10. The effect of a tax increase 
on revenues was estimated as
where Vr is the calculated variation in revenues; Δc 
represents the expected variation in consumption due to 
the price increase as a proportion of the baseline 
consumption; ΔP represents the change in cigarette 
prices as a proportion of the baseline price; and pV 
represents the proportion of the price, before the price 
increase, represented by taxes.
Role of the funding source
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had 
full access to all the data in the study and had final 

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Epidemiological and economic data were obtained 
for each country for Jan 1 to Dec 31, 2015. The main 
parameters included in the model are shown in table 1 
and in the appendix (p 1). After the model was calibrated, 
the mean rate of each disease-specific mortality predicted 
by the model was within 10% of the corresponding 
mortality reported by national statistics in each country 
(correlation between the observed and expected results 
yielded R² values ranging from 0·700 to 0·999). External 
validation also showed a good correlation between the 
results predicted by the model and those observed in 
epidemiological studies. The results of the calibration 
and validation process in Argentina are shown in the 
appendix (p 5).
In total, in the 12 countries included in this study, 
smoking is estimated to cause 345 373 (12%) of the total 
2 860 921 adult deaths, 2·21 million disease events, 
8 774 402 healthy years of life lost because of premature 
mortality and disability, and US$26·9 billion in direct 
medical costs every year (table 2). We estimated that 
cancer, COPD, and cardiovascular disease attributable to 
smoking caused the largest burden in terms of both lost 
health and medical costs. Tobacco use was responsible 
for an estimated 51 414 (79%) of 65 306 deaths and 
$2471·3 million (80%) of $3084·5 million in medical 
costs due to lung cancer, 76 730 (74%) of 103 142 deaths 
and $8640·0 million (72%) of $12 028·9 million 
in medical costs due to COPD, and 76 896 (16%) of 
494 755 deaths and $7612·3 million (22%) of 
$33 961·2 million in medical costs due to cardiovascular 
disease (table 2).
In Chile, the country with the highest smoking 
prevalence, 19 731 (18%) of 107 545 deaths among adults 
were estimated to be related to smoking (the largest 
proportion of all of the 12 countries); the direct medical 
cost of smoking was estimated to be about US$1·9 billion. 
Brazil, the country with the largest population in the 
group, showed the largest estimated absolute number 
of deaths and costs attributable to tobacco with 
156 217 annual deaths and a cost of approximately 
$11·8 billion, followed by Mexico with 49 189 smoking-
related deaths and approximately $4·8 billion in costs. 
COPD was the single disease that caused the highest 
estimated proportion of smoking-related deaths (table 2). 
In the 12 countries combined, COPD was estimated 
to cause more than 76 000 smoking-related deaths and 
approximately $8·7 billion in costs. All cancers com-
bined, including lung cancer, accounted for an estimated 
104 000 deaths and $5·7 billion in costs in all countries.
Health-care costs attributable to smoking repre-
sented an estimated 6·9% of the health budgets of these 
12 countries, ranging from 3·5% in Honduras to 
16·7% in Uruguay; these health-care costs represented a 
mean of 0·6% of gross domestic product, ranging from 
0·3% in Honduras to 1·5% in Uruguay. None of the 
countries recover through tobacco taxes the total of the 
resources allocated to treat smoking-attrib utable diseases; 
we estimated that tax revenues from cigarette sales cover 
36·0% of health expenditures attrib utable to smoking 
across all 12 countries. We estimated that Bolivia recovers 
6·0% of the expenses and that Chile, with the highest 
tobacco taxes in the region, recovers 78·9% of the health 
costs attributable to tobacco (table 3).
We estimated that a 50% increase in the price of 
cigarettes through taxes in the 12 Latin American 
countries analysed could produce substantial health and 
economic benefits in the next 10 years. In these 
12 countries, we estimated that this price increase would 
lead to the aversion of 314 314 deaths, and approximately 
1·27 million cardiovascular, cerebrovascular, and cancer 
events (table 4). We also estimated that this tax policy 
would result in gaining almost 8·67 million healthy life 
years by averting premature death and disability. Approxi-
mately $23·4 billion would be saved in health-care costs, 
and tax revenues could increase by approximately 
$35·1 billion, resulting in a total estimated economic 
benefit of $58·6 billion.
The health and economic effects of a price increase of 
tobacco in each country depend on several factors, such 
as the prevalence of smoking, the current level of taxes, 
the elasticity of demand, and health-care costs. The figure 
shows the expected health and economic gains from a 
50% increase in tobacco price in each country over 
10 years. The health benefits are expressed as deaths 
avoided as a proportion of the current number of deaths 
that are attributable to smoking in each country; the 
economic benefits due to a reduction of health-care costs 
and increased tax collection are expressed as a proportion 
Smoking-attributable annual direct medical costs Proportion of direct 
medical costs recovered 
through tobacco taxes
Total costs, $ As a proportion of 
total health 
expenditure
As a proportion 
of GDP
Argentina $3 817 334 778 7·3% 0·6% 55·3%
Bolivia $249 794 501 11·8% 0·8% 6·0%
Brazil $11 830 140 911 5·7% 0·7% 25·6%
Chile $1 901 333 725 9·4% 0·8% 78·9%
Colombia $1 708 544 794 9·7% 0·6% 10·2%
Costa Rica $241 569 268 5·7% 0·4% 26·1%
Ecuador $476 043 817 5·6% 0·5% 41·0%
Honduras $56 355 353 3·5% 0·3% 51·5%
Mexico $4 767 757 221 8·0% 0·4% 46·9%
Paraguay $301 307 227 10·7% 0·8% 20·2%
Peru $796 045 581 8·0% 0·4% 9·2%
Uruguay $800 146 359 16·7% 1·5% 26·4%
All 12 countries $26 946 373 535 6·9% 0·6% 36·0%
All costs are in 2015 US dollars. GDP, total health expenditure as a proportion of GDP, and total tobacco tax revenue for 
each country are shown in table 1. GDP=gross domestic product.
Table 3: Proportion of total health expenditures and GDP represented by smoking-attributable direct 
















of the country’s gross domestic product. In the long 
term, a 50% price increase of tobacco could prevent 
between 7·6% (Argentina) and 32·4% (Bolivia) of all 
deaths currently attributable to smoking per year and 
could produce economic gains equivalent to 0·09% of 
gross domestic product in Peru, to up to 0·31% of gross 
domestic product in Uruguay. In some countries, these 
economic benefits would be produced mainly by avoided 
health-care costs (eg, in Bolivia, Colombia, and Peru) and 
in others, by increased tax collection (eg, in Argentina, 
Honduras, and Mexico).
Discussion
To the best of our knowledge, this is the first study to 
analyse the disease burden of smoking in Latin America 
with an economic model developed in the region. Our 
findings show that smoking represents a substantial 
health and economic burden in 12 countries in Latin 
America, with more than 345 000 deaths, 2·2 million 
disease events, and $26·9 billion in medical costs that 
are estimated to be directly attributable to tobacco every 
year. Tax collections from tobacco products are barely 
enough to cover a third of these costs.
Taxation can be an effective strategy to reduce smoking, 
improve population health, and reduce health-care costs. 
According to our estimations, an increase of just 50% in 
the price of cigarettes through taxation, which is feasible 
in the region given the low prevailing prices, would pre-
vent more than 300 000 deaths and more than 1 million 
cardiovascular events, strokes, and cancers, and would 
reduce health-care costs and increase tax revenues, leading 
to a total economic benefit of $58·6 billion over 10 years.
Our findings are consistent with previous studies in 
terms of both the estimation of the overall burden of 
tobacco and the potential reduction of this burden 
through taxation. Smoking is a leading risk factor for 
early death and disability in more than 100 countries and 
is responsible for 11·5% of deaths and 6·0% of disability-
adjusted life-years worldwide.31 Previous studies have 
estimated that health-care expenditures due to smoking-
attributable diseases totalled 5·7% of global health 
expenditures in 2012.4 It has been suggested that if 
cigarette prices increased 50% worldwide, approximately 
20 million people could avoid poverty, millions of 
premature deaths could be prevented, and extra tobacco 
revenue could partly finance health care.32
A simulation model applied to 181 countries showed 
that a 43% increase in the retail price of cigarettes 
through taxes would lead to 15 million fewer smoking-
attributable deaths among the adults who were alive 
in 2014, and cigarette excise revenue would increase 
by 47%.33 In the EU, if all countries charged higher taxes, 
consumption of tobacco would be reduced, and revenue 
would be increased by an average of 6·76% with a 
10% price increase.34
Previous studies have analysed the potential effect of 
a price increase on cigarette consumption in Latin 
America. In Colombia, one such study estimated that 
a 50% increase in the price of cigarettes, bringing it 
closer to the regional average, could result in a 31% 
decrease in consumption.26 In Mexico, the SimSmoke 
model esti mated that increasing excise taxes to 70% of 
the price could reduce the smoking prevalence by 16%, 
and in Argentina, it was estimated that an 80% price 
increase would reduce smoking prevalence by 20% 
within 30 years.35,36
A limitation of our study is that, although it offers a 
robust estimate of the health and financial burden of 
smoking using the best available information in each 
country and applying a uniform and replicable method, 






















Argentina 27 469 660 323 43 505 15 761 12 691 $2266 $9738 $12 004
Bolivia 10 868 279 060 6330 11 960 3141 $655 $43 $699
Brazil 136 482 4 076 353 507 451 100 365 64 383 $9761 $10 640 $20 401
Chile 20 502 536 701 25 794 23 996 8273 $2052 $3749 $5801
Colombia 45 049 1 173 703 142 162 62 967 17 401 $2554 $393 $2948
Costa Rica 1698 42 592 6847 787 726 $237 $209 $446
Ecuador 4946 133 607 3321 4221 1726 $294 $801 $1094
Honduras 1306 33 692 2992 416 587 $50 $238 $289
Mexico 38 358 1 047 689 99 066 24 113 14 418 $3502 $8138 $11 640
Paraguay 2507 67 537 7383 2112 1056 $221 $252 $473
Peru 20 588 505 153 12 482 19 343 7433 $1067 $344 $1411
Uruguay 4541 108 751 7485 1345 2652 $788 $586 $1374
Total 314 314 8 665 161 864 818 267 386 134 487 $23 448 $35 131 $58 580
All economic effects are in 2015 US dollars. *Healthy life-years lost averted are those that would have been lost because of premature mortality or quality of life losses.
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our results are highly dependent on the quality of 
information in each country. The availability and quality 
of epidemiological and cost information in Latin 
America is very variable and, in some countries, even 
basic data such as mortality statistics can be imprecise. 
Similar to all model-based studies, there is also 
uncertainty around many of the model’s assumptions. 
For example, many changes could happen in the future 
that would affect the 10-year benefit estimate (eg, 
changes in smoking behaviours, emergence of new 
treatments, changes in health-care costs). Despite these 
limitations, both the burden attributable to smoking 
and the benefits of tobacco tax increases evidenced by 
our study are probably conservative estimates. Our 
analysis considered only the direct medical costs 
generated by tobacco consumption, which are only a 
portion of the total financial burden imposed by 
smoking on countries. Several studies have shown that 
the financial burden of smoking could be double or 
triple the estimates based on direct medical costs if the 
Figure: Estimated proportion of deaths averted and economic benefits during the 10 years after a 50% increase in the price of cigarettes in 12 Latin American countries
In each country, deaths averted are expressed as a proportion of current total tobacco-attributable deaths. Economic gains (due to increased tax revenues and reduction of direct medical costs) are 
















cost of lost productivity and other social costs are also 
considered.4,37,38 Results obtained using our model 
showed that in Brazil, when a conser vative estimate of 
the productivity losses caused by tobacco was included 
in the analysis, the estimate of the economic burden 
of smoking increased by 50%, from 39·4 billion to 
59·1 billion Brazilian Reais per year.39 Another important 
limitation is that our model did not include the effects 
of passive smoking, perinatal effects, or other effects 
(such as losses from fires), although we did include an 
estimation of the effect of these factors based on 
estimates from other studies. For all these reasons, 
although our study is more comprehensive than most of 
the analyses that had been done so far in Latin America, 
our estimates of the potential benefits of higher tobacco 
taxes are probably an underestimation.
Although taxation could be the best strategy to curb the 
use of tobacco, many countries are lagging behind the 
level of taxation recommended by WHO. Cigarettes 
remain affordable, and prices are manipulated by the 
tobacco industry to ameliorate the effects of excise tax on 
smokers. Our results show that tobacco tax increases 
could successfully avert deaths and disability, as well as 
substantially reduce spending on health care, resulting 
in large net economic benefits in these 12 Latin American 
countries.
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